Peter C M van de Kerkhof
Department of Dermatology, Radboud University Medical Center, Nijmegan, Netherlands | Department of Dermatology, Radboud Institute for Health Sciences, Nijmegen, the ...
Is this your profile? Claim your profile Copy URL Embed Link to your profile
Peter C M van de:Expert Impact
Concepts for whichPeter C M van dehas direct influence:Skin diseases,Patients psoriasis,Scalp psoriasis,Calcipotriol ointment,Psoriasis patients,Epidermal proliferation,Plaque psoriasis,Atopic dermatitis.
Peter C M van de:KOL impact
Concepts related to the work of other authors for whichfor which Peter C M van de has influence:Psoriatic arthritis,Patients psoriasis,Atopic dermatitis,Skin diseases,Quality life,Photodynamic therapy,Monoclonal antibodies.
KOL Resume for Peter C M van de Kerkhof
Department of Dermatology, Radboud University Medical Center, Nijmegan, Netherlands
Department of Dermatology, Radboud Institute for Health Sciences, Nijmegen, the Netherlands.
Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands
Radboud University Medical Center, Nijmegen, The Netherlands
Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands, View further author information
Radboud Institute for Molecular Life Sciences (RIMLS), and, Radboud Institute for Health Sciences (RIHS), Nijmegen, Philips Research Eindhoven, Philips Electronics Nederland B.V., Eindhoven, and, RiverD International B.V., Rotterdam, The Netherlands
Afdeling Dermatologie, Radboudumc, Huispostnummer 374, Postbus 9101, 6500 HB, Nijmegen, Nederland
Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Departments of, Medical Psychology, Dermatology and, Health Evidence, Radboud university medical center, and, Department of Dermatology, Canisius-Wilhelmina Hospital, Nijmegen, Department of Dermatology, Rijnstate Hospital, Velp, and, Department of Dermatology, Ziekenhuisgroep Twente, Almelo, The Netherlands
Department of Dermatology, Radboud university medical center
Radboud University Medical Center, Department of Dermatology, Nijmegen, The Netherlands
Dept of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands
Dermatology Department, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Departments of Dermatology.
Department of Dermatology, Radboud University Nijmegen Medical Centre, 6525 GL Nijmegen, the Netherlands
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
University Hospital Nijmegen, Nijmegen, the Netherlands (P.K.)
Departments of Dermatology
Dermatologikum, Hamburg, Germany;, University Hospital Sint-Rafaël, Leuven, Belgium;, University Hospital, Nijmegen, and, Wyeth Research, Hoofddorp, The Netherlands;, Wyeth Research, Paris, France;, Wyeth Research, Collegeville, Pa., USA
Department of Dermatology, 370 Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands
Department of Dermatology, UMC St Radboud, PO Box 9101, 65 HB Nijmegen, the Netherlands
Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, 652 GA, Nijmegen, The Netherlands
Department of Dermatology, Radboud University Nijmegen, Medical Center, Nijmegen, The Netherlands
Department of Dermatology, Radboud University Nijmegen Medical Centre, GL Nijmegen, The Netherlands
From the Department of Dermatology, University Medical Center Nijmegen The Netherlands
Departments of Dermatology and
From Waterlooa; University of Western Ontariob; Virga Jesse Ziekenhuis, Hasseltc; Bispebjerg Hospital, Copenhagend; University Hospital Kuopioe; Hopital Saint Eloi, Montpellierf; Klinikum der Goethe-Universität, Frankfurtg; Hume St Hospital, Dublinh; Kliniek voor Huidziekten, Nijmegeni; Sentralsjukehuset i Møre og Romsdal, Ålesundj; Universital Hospital, Lundk; Dermatologische Klinik Universitätsspital Zürichl; Leo Pharmaceuticalsm; Hammersmith Hospital, London.n
|single expression extent||#1|
|treatments ltb4induced inflammatory||#1|
|dithranol irritation patients||#1|
|treg psoriatic skin||#1|
|vivo cd11b upregulation||#1|
|psoriasis clearance time||#1|
|psoriatic lesion psoriasis||#1|
|dermis cd45ro cells||#1|
|adalimumab treatment parameters||#1|
|16 weeks cyclosporin||#1|
|pharmacological effects vml||#1|
|bexarotene epidermal proliferation||#1|
|betamethasone dipropionate treatment||#1|
|iqr median pga||#1|
|vivo diagnosis bcc||#1|
|effectiveness leg elevation||#1|
|general strategy implementation||#1|
|margin psoriasis plaque||#1|
|frozen sections hbd2||#1|
|positive influence treatments||#1|
|patients skin diseases||#1|
|psoriasis childhood psoriasis||#1|
|tcf active interventions||#1|
|sites psoriasis lesion||#1|
|dithranol cream treatment||#1|
|keratin egfr expression||#1|
|vml placebotreated patients||#1|
|differentiation 3 months||#1|
|psoriasis etanercept treatment||#1|
|tcell subsets pb||#1|
Prominent publications by Peter C M van de Kerkhof
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
[ PUBLICATION ]
BACKGROUND: Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis.
METHODS: In two prospective, double-blind, multicentre, phase 3 studies (UNCOVER-2 and UNCOVER-3), eligible patients were aged 18 years or older, had a confirmed diagnosis of ...
|Known for Placebo Etanercept | Patients Ixekizumab | 2 Weeks | Nonsteroidal Antibodies | Phase 3|
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
[ PUBLICATION ]
BACKGROUND: New therapeutic options are needed for patients with psoriasis. Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis. In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.
METHODS: In this phase 3, randomised, multicentre, double-dummy, placebo-controlled, 12-week, non-inferiority trial, adult patients with chronic stable plaque ...
|Known for Tofacitinib Etanercept | Placebo Patients | Chronic Plaque | Phase 3 | 5 10|
Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T‐cell subsets, epidermal proliferation and differentiation
[ PUBLICATION ]
BACKGROUND: T-cell infiltration in plaque psoriasis has recently been an important subject of investigation. Interestingly, comparative analyses of the disease-specific composition of the lesional T-cell infiltrate in plaque psoriasis and other inflammatory dermatoses have only sparsely been performed.
PATIENTS AND METHODS: ...
|Known for Lichen Planus | Atopic Dermatitis | Plaque Psoriasis | Epidermal Proliferation | Cell Subsets|
BACKGROUND: Knowledge about quality of life and sexual health in patients with genital psoriasis is limited.
OBJECTIVES: We studied quality of life and sexual function in a large group of patients with genital psoriasis by means of validated questionnaires. In addition, we evaluated whether sufficient attention is given by healthcare professionals to sexual problems in patients with psoriasis, as perceived by the patients.
METHODS: A self-administered questionnaire was sent to 1579 ...
|Known for Sexual Health | Genital Psoriasis | Quality Life | Psychological Surveys | Validated Questionnaires|
Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept
[ PUBLICATION ]
BACKGROUND: Knowledge on the sequential treatment of psoriasis with biologics with regard to efficacy and safety is sparse. This also applies to the efficacy and safety of adalimumab in patients previously treated with etanercept. The relationship between the reasons for discontinuation of etanercept and the response to adalimumab is not clear in psoriasis.
OBJECTIVES: To evaluate the efficacy and safety of adalimumab in patients with psoriasis with primary failure, secondary failure or ...
|Known for Patients Psoriasis | Secondary Failure | Etanercept Adalimumab | Monoclonal Antibodies | Efficacy Safety|
Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice
[ PUBLICATION ]
BACKGROUND: Physical symptoms of skin diseases have been shown to negatively affect patients' wellbeing. Although insight into physical symptoms accompanying skin diseases is relevant for the management and treatment of skin diseases, the prevalence of physical symptoms among patients with skin diseases is a rather unexplored territory.
OBJECTIVES: The goal of the present study was to examine the prevalence of physical symptoms of itch, pain and fatigue in patients with skin ...
|Known for Skin Diseases | Physical Symptoms | Fatigue Patients | Itch Pain | General Practice|
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial with open‐label extension
[ PUBLICATION ]
BACKGROUND: In previous studies, etanercept 25 mg twice weekly (BIW) or 50 mg BIW significantly reduced disease severity in patients with plaque psoriasis and demonstrated a favourable safety profile.
OBJECTIVES: To assess the efficacy and safety of etanercept 50 mg administered once weekly (QW) compared with placebo in patients with moderate-to-severe plaque psoriasis over 24 weeks.
METHODS: This study was conducted in two parts: (i) a 12-week, double-blind, placebo-controlled phase, in ...
|Known for Etanercept 50 | Plaque Psoriasis | Week Patients | Placebo Qw | Baseline Pasi|
Physical complaints, such as pain, can be effectively reduced by placebo effects through induction of positive expectations, or increased by nocebo effects through induction of negative expectations. In the present study, verbally induced nocebo and placebo effects on itch were experimentally investigated for the first time. In part 1, the role of verbal suggestions in inducing nocebo effects on itch and pain was investigated. All subjects received the same somatosensory quantitative ...
|Known for Verbal Suggestions | Placebo Effects | Itch Pain | Histamine Application | Induction Nocebo|
BACKGROUND: Biologic agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known. We compared two biologic agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor alpha), for the treatment of psoriasis.
METHODS: We randomly assigned 903 patients with moderate-to-severe psoriasis to receive subcutaneous injections of either 45 ...
|Known for Ustekinumab Etanercept | Pasi Week | 75 Improvement | Patients Psoriasis | Monoclonal Antibodies|
Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis
[ PUBLICATION ]
BACKGROUND: Chronic skin diseases, such as atopic dermatitis and psoriasis, are known to affect quality of life by heightening psychological distress. Knowledge about factors contributing to psychological distress is essential for supporting physicians in diagnostic and multidisciplinary treatment options for patients psychologically at risk.
OBJECTIVES: To examine whether generic physical, psychological and social factors relevant to patients with chronic diseases might contribute to ...
|Known for Psychological Distress | Atopic Dermatitis | Chronic Skin Diseases | Patients Psoriasis | Social Support|
Biochemical and biophysical assessment of MTX‐induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan® predicts the absence of significant liver fibrosis
[ PUBLICATION ]
BACKGROUND: Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients. To monitor this serial liver biopsies were performed. The Fibroscan and the Fibrotest are two novel, non-invasive methods that might be able to assess MTX-induced hepatic fibrosis.
AIM: Evaluating the accuracy and feasibility of the Fibroscan and Fibrotest to detect significant MTX-induced liver fibrosis in psoriasis patients.
METHODS: We assessed 24 psoriasis patients who had a recent liver ...
|Known for Psoriasis Patients | Liver Fibrosis | Fibroscan Fibrotest | Methotrexate Mtx | Noninvasive Methods|
Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris
[ PUBLICATION ]
The therapeutic efficacy and tolerability of calcipotriol ointment and betamethasone valerate ointment in psoriasis were compared in a multicentre, prospective, randomised, double-blind, right/left trial. 345 inpatients and outpatients with psoriasis vulgaris of symmetrical distribution were treated twice daily for 6 weeks with calcipotriol ointment 50 micrograms/g and betamethasone ointment 0.1% randomly assigned to opposite sides of the body. The main outcome measures--the psoriasis ...
|Known for Betamethasone Valerate | Psoriasis Vulgaris | 6 Weeks | Calcipotriol Ointment | Thickness Scaling|
Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomize
[ PUBLICATION ]
BACKGROUND: Calcipotriol and betamethasone dipropionate are both widely used, effective treatments for psoriasis. Vitamin D analogues and topical corticosteroids have different mechanisms of action in the treatment of psoriasis. A new vehicle has been developed in order to contain both calcipotriol (50 micro g g-1) and betamethasone dipropionate (0.5 mg g-1) in an ointment form. By using calcipotriol and a corticosteroid together, greater efficacy may be achieved than by using either ...
|Known for Psoriasis Vulgaris | Efficacy Safety | Daily Calcipotriol | Betamethasone Dipropionate | Ointment Formulation|
Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue.
[ PUBLICATION ]
The structure and function of the tumor microvasculature is of great interest for cancer biology, diagnosis, and therapy. The distribution of endothelial cells, pericytes, and basal lamina in tumors is not well documented. In this study, the authors investigated the distribution of markers for these different components in a series of malignant human tumors and in human granulation tissue, both situations with extensive angiogenesis. Their results show a striking heterogeneity in the ...
|Known for Granulation Tissue | Endothelial Cells | Differential Expression | Basal Lamina | Tumor Vasculature|
Placebo and nocebo effects are known to play a key role in treatment effects in a wide variety of conditions. These effects have frequently been investigated with regard to pain and also in other physical sensations, but have hardly been investigated with regard to itch. In addition, neither in pain nor in any other physical sensation, the single and combined contribution of the expectancy mechanisms of conditioning and verbal suggestion have ever been investigated in both placebo and ...
|Known for Verbal Suggestion | Nocebo Effects | Pain Itch | Physical Sensations | Conditioning Placebo|